# A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

> **NCT06063967** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 289 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Risankizumab SC
- **DRUG:** Placebo for risankizumab

## Key facts

- **NCT ID:** NCT06063967
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063967, "A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06063967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*